Interactions between the lung microbiome and host immunity in chronic obstructive pulmonary disease

作     者：Yixing Zhu De Chang Yixing Zhu;De Chang

作者机构：Graduate School of The PLA General HospitalBeijingChina Department of Respiratory and Critical Care MedicineEighth Medical CenterDepartment of Respiratory and Critical Care Seventh Medical CenterChinese PLA General HospitalBeijingChina 

出 版 物：《Chronic Diseases and Translational Medicine》 (慢性疾病与转化医学（英文版）)

年 卷 期：2023年第9卷第2期

页      面：104-121页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Three Talents One Team Project of The Joint Logistic Support Force,Grant/Award Number:2021-439 National Key Research and Development Program of China,Grant/Award Number:No.2021YFC2302300 The Project of High-level Innovative Talents of the Armed Forces,Grant/Award Number:2022QN07351 

主　　题：adaptive immune response chronic obstructive pulmonary disease innate immune response microbiome 

摘      要：Chronic obstructive pulmonary disease(COPD)is a common chronic respiratory disease and the third leading cause of death *** in next-generation sequencing technology have improved microbiome analysis,which is increasingly recognized as an important component of disease *** to the gut,the lung is a biosphere containing billions of microbial *** lung microbiome plays an important role in regulating and maintaining the host immune *** microbiome composition,metabolites of microorganisms,and the interactions between the lung microbiome and the host immunity profoundly affect the occurrence,development,treatment,and prognosis of *** this review,we drew comparisons between the lung microbiome of healthy individuals and that of patients with ***,we summarize the intrinsic interactions between the host and the overall lung microbiome,focusing on the underlying mechanisms linking the microbiome to the host innate and adaptive immune response ***,we discuss the possibility of using the microbiome as a biomarker to determine the stage and prognosis of COPD and the feasibility of developing a novel,safe,and effective therapeutic target.